Drug intelligence / Profile preview

EX-042

Development stage: Preclinical
Lead developer: Excelsior
Modality: Small Molecules

Overview

EX-042 is a small-molecule modulator of the Transforming Growth Factor-beta (TGF-β) signaling pathway, currently in preclinical development by Excelsior Group. The drug is being investigated for two primary therapeutic applications: the promotion of wound healing and the treatment of pulmonary arterial hypertension (PAH). By targeting TGF-β, EX-042 aims to regulate tissue repair processes and address the pathological vascular remodeling associated with PAH. It is a lead candidate within Excelsior's TGF-β Research Center, which focuses on developing inhibitors with novel mechanisms of action to treat rare diseases, fibrosis, and inflammation.

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on EX-042.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EX-042.

Explore the full profile